These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 11771748)

  • 21. Down's syndrome: a pathology involving the lack of balance of reactive oxygen species.
    Kedziora J; Bartosz G
    Free Radic Biol Med; 1988; 4(5):317-30. PubMed ID: 2966094
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Copper accumulation in the brain of Down syndrome model mice and its pathophysiological significance].
    Ishihara K; Kawashita E; Akiba S
    Nihon Yakurigaku Zasshi; 2019; 154(6):335-339. PubMed ID: 31787686
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Using mouse models to explore genotype-phenotype relationship in Down syndrome.
    Salehi A; Faizi M; Belichenko PV; Mobley WC
    Ment Retard Dev Disabil Res Rev; 2007; 13(3):207-14. PubMed ID: 17910089
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dendrites, dementia and the Down syndrome.
    Takashima S; Ieshima A; Nakamura H; Becker LE
    Brain Dev; 1989; 11(2):131-3. PubMed ID: 2523670
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neuronal apoptosis inhibitory protein (NAIP)-like immunoreactivity in brains of adult patients with Down syndrome.
    Seidl R; Bajo M; Böhm K; LaCasse EC; MacKenzie AE; Cairns N; Lubec G
    J Neural Transm Suppl; 1999; 57():283-91. PubMed ID: 10666683
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neuronal cell death in Down's syndrome.
    Sawa A
    J Neural Transm Suppl; 1999; 57():87-97. PubMed ID: 10666670
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular neuropathology of transgenic mouse models of Down syndrome.
    Cairns NJ
    J Neural Transm Suppl; 2001; (61):289-301. PubMed ID: 11771752
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differences between GABA levels in Alzheimer's disease and Down syndrome with Alzheimer-like neuropathology.
    Seidl R; Cairns N; Singewald N; Kaehler ST; Lubec G
    Naunyn Schmiedebergs Arch Pharmacol; 2001 Feb; 363(2):139-45. PubMed ID: 11218066
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Activity-Dependent Dysfunction in Visual and Olfactory Sensory Systems in Mouse Models of Down Syndrome.
    William CM; Saqran L; Stern MA; Chiang CL; Herrick SP; Rangwala A; Albers MW; Frosch MP; Hyman BT
    J Neurosci; 2017 Oct; 37(41):9880-9888. PubMed ID: 28899917
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Down syndrome: the brain in trisomic mode.
    Dierssen M
    Nat Rev Neurosci; 2012 Dec; 13(12):844-58. PubMed ID: 23165261
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increased App expression in a mouse model of Down's syndrome disrupts NGF transport and causes cholinergic neuron degeneration.
    Salehi A; Delcroix JD; Belichenko PV; Zhan K; Wu C; Valletta JS; Takimoto-Kimura R; Kleschevnikov AM; Sambamurti K; Chung PP; Xia W; Villar A; Campbell WA; Kulnane LS; Nixon RA; Lamb BT; Epstein CJ; Stokin GB; Goldstein LS; Mobley WC
    Neuron; 2006 Jul; 51(1):29-42. PubMed ID: 16815330
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Integration-free induced pluripotent stem cells model genetic and neural developmental features of down syndrome etiology.
    Briggs JA; Sun J; Shepherd J; Ovchinnikov DA; Chung TL; Nayler SP; Kao LP; Morrow CA; Thakar NY; Soo SY; Peura T; Grimmond S; Wolvetang EJ
    Stem Cells; 2013 Mar; 31(3):467-78. PubMed ID: 23225669
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mechanisms of neuronal death in Down's syndrome.
    Nagy Z
    J Neural Transm Suppl; 1999; 57():233-45. PubMed ID: 10666679
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Apoptosis in Down's syndrome: lessons from studies of human and mouse models.
    Rueda N; Flórez J; Martínez-Cué C
    Apoptosis; 2013 Feb; 18(2):121-34. PubMed ID: 23224708
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alpha- and beta-secretase activity as a function of age and beta-amyloid in Down syndrome and normal brain.
    Nistor M; Don M; Parekh M; Sarsoza F; Goodus M; Lopez GE; Kawas C; Leverenz J; Doran E; Lott IT; Hill M; Head E
    Neurobiol Aging; 2007 Oct; 28(10):1493-506. PubMed ID: 16904243
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neurodevelopmental delay, motor abnormalities and cognitive deficits in transgenic mice overexpressing Dyrk1A (minibrain), a murine model of Down's syndrome.
    Altafaj X; Dierssen M; Baamonde C; Martí E; Visa J; Guimerà J; Oset M; González JR; Flórez J; Fillat C; Estivill X
    Hum Mol Genet; 2001 Sep; 10(18):1915-23. PubMed ID: 11555628
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The brain in Down syndrome (TRISOMY 21).
    Lubec G; Engidawork E
    J Neurol; 2002 Oct; 249(10):1347-56. PubMed ID: 12382149
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Beta-amyloid precursor protein, ETS-2 and collagen alpha 1 (VI) chain precursor, encoded on chromosome 21, are not overexpressed in fetal Down syndrome: further evidence against gene dosage effect.
    Engidawork E; Baiic N; Fountoulakis M; Dierssen M; Greber-Platzer S; Lubec G
    J Neural Transm Suppl; 2001; (61):335-46. PubMed ID: 11771756
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular mapping of Alzheimer-type dementia in Down's syndrome.
    Prasher VP; Farrer MJ; Kessling AM; Fisher EM; West RJ; Barber PC; Butler AC
    Ann Neurol; 1998 Mar; 43(3):380-3. PubMed ID: 9506555
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mental retardation in Down syndrome: from gene dosage imbalance to molecular and cellular mechanisms.
    Rachidi M; Lopes C
    Neurosci Res; 2007 Dec; 59(4):349-69. PubMed ID: 17897742
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.